tiprankstipranks
Clovis Oncology (DE:C6O)
XETRA:C6O

Clovis Oncology Stock Price & Analysis

0 Followers

C6O Stock Chart & Stats

Day’s Range€0 - €0
52-Week Range― - ―
Previous Close€1.11
Volume0.00
Average Volume (3M)10.42K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)€94.58M
Total Debt (Recent Filing)€580.88M
P/E RatioN/A
Beta-0.99
Next EarningsNov 02, 2022
EPS Estimate-€0.42
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price TargetN/A
EPS (TTM)N/A
Shares Outstanding144,480,215
R-Squared0.04
Standard Deviation0.37
10 Day Avg. Volume293
30 Day Avg. Volume10,424
P/B Ratio-0.31
P/S Ratio1.19
P/CF RatioN/A
P/FCF Ratio-0.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target UpsideN/A
Rating ConsensusHold
Alpha-0.03
Number of Analyst Covering1


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

C6O FAQ

What was Clovis Oncology’s price range in the past 12 months?
Currently, no data Available
What is Clovis Oncology’s market cap?
Currently, no data Available
When is Clovis Oncology’s upcoming earnings report date?
Clovis Oncology’s upcoming earnings report date is Nov 02, 2022 which is in 33 days.
    How were Clovis Oncology’s earnings last quarter?
    Clovis Oncology released its earnings results on Aug 08, 2022. The company reported -€0.516 earnings per share for the quarter, missing the consensus estimate of -€0.428 by -€0.088.
      Is Clovis Oncology overvalued?
      According to Wall Street analysts Clovis Oncology’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Clovis Oncology pay dividends?
        Clovis Oncology does not currently pay dividends.
        What is Clovis Oncology’s EPS estimate?
        Clovis Oncology’s EPS estimate is -€0.42.
          How many shares outstanding does Clovis Oncology have?
          Currently, no data Available
          What happened to Clovis Oncology’s price movement after its last earnings report?
          Clovis Oncology reported an EPS of -€0.516 in its last earnings report, missing expectations of -€0.428. Following the earnings report the stock price went down -10.179%.
            Which hedge fund is a major shareholder of Clovis Oncology?
            Among the largest hedge funds holding Clovis Oncology’s share is Gamco Investors, Inc. ET AL. It holds Clovis Oncology’s shares valued at 285K.

              ---

              Clovis Oncology Stock Analysis

              Smart ScoreNeutral
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10
              4

              Analyst Consensus

              Hold
              Average Price Target:

              Blogger Sentiment

              Bullish
              DE:C6O Sentiment 100% Sector Average 70%

              Insider Transactions

              ▼ Sold Shares
              Worth $13.1K over the Last 3 Months

              News Sentiment

              Neutral
              Bullish 50% Bearish 50%

              Technicals

              SMA
              Negative
              20 days / 200 days
              Momentum
              -74.73%
              12-Months-Change

              Fundamentals

              Return on Equity
              N/A
              Trailing 12-Months
              Asset Growth
              -31.35%
              Trailing 12-Months
              The Clovis Oncology Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
              Learn more about TipRanks Smart Score

              Company Description

              Clovis Oncology

              Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of cancer treatments. Its marketed product Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is offered for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

              ---
              Similar Stocks
              Company
              Price & Change
              Follow
              AbbVie
              Amgen
              Gilead Sciences
              Moderna
              Vertex Pharmaceuticals

              Popular Stocks

              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis